← Back to Search

Single Blood Draw for Non-alcoholic Fatty Liver Disease

N/A

Waitlist Available

Research Sponsored by Regeneron Pharmaceuticals

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day 1

Awards & highlights

Study Summary

This trial will help identify individuals that carry genetic variants that make them more likely to develop Non-alcoholic Steatohepatitis, a disease of the liver.

Eligible Conditions

Non-alcoholic Fatty Liver Disease

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ day 1

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~day 1

This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Hydroxysteroids

Genotype frequencies of rs738409 in patatin-like phospholipase domain containing 3 (PNPLA3)

Secondary outcome measures

Distribution of FIB-4 scores across participants with different genotypes of rs738409 in PNPLA3B13

Distribution of fibrosis-4 (FIB-4) scores across participants with different genotypes of rs72613567 in HSD17B13

Trial Design

1Treatment groups

Experimental Treatment

Group I: Single Blood DrawExperimental Treatment1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

No Intervention

2017

Completed Phase 1

~4840

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Regeneron PharmaceuticalsLead Sponsor

613 Previous Clinical Trials

374,447 Total Patients Enrolled

3 Trials studying Non-alcoholic Fatty Liver Disease

320 Patients Enrolled for Non-alcoholic Fatty Liver Disease

Clinical Trial ManagementStudy DirectorRegeneron Pharmaceuticals

258 Previous Clinical Trials

245,687 Total Patients Enrolled

3 Trials studying Non-alcoholic Fatty Liver Disease

320 Patients Enrolled for Non-alcoholic Fatty Liver Disease

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the number of health care facilities that are conducting this experiment?

"Currently, patients are being enrolled at Mt. Olympus Medical Research in Houston, Texas, Links Clinical Trials in Miami, Florida and Miami Clinical Research in Coronado California as well as 30 supplementary medical sites."

Answered by AI

Does this research endeavor extend to those under 30 years of age?

"For this research, participants must be elder to 18 years and younger than 75."

Answered by AI

How many individuals are collaborating in this clinical experiment?

"This trial necessitates 8000 individuals that meet the criteria to be viable participants. The sponsor, Regeneron Pharmaceuticals, will run the clinical trial from two locations: Mt. Olympus Medical Research in Houston and Links Clinical Trials in Miami."

Answered by AI

Is registration for this experiment currently available?

"Confirmed. Per the details available on clinicaltrials.gov, this medical experiment is recruiting eligible candidates and was initially posted on December 9th 2021 before undergoing its most recent revision on October 11th 2022."

Answered by AI

Could I meet the criteria for involvement in this investigation?

"In order to participate in this medical trial, individuals must possess nonalcoholic steatohepatitis and be between 18-75 years of age. Approximately 8 thousand participants are required for the study's completion."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH)

2021. "Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05423327.